Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art

Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Gluco...

Full description

Saved in:
Bibliographic Details
Published inIberoamerican journal of medicine Vol. 5; no. 2; pp. 68 - 77
Main Authors Meza-González, Yilmar Alexader, Alfonso-Arrieta, Natalia, Salas-Solorzano, Stephany, Florez-Garcia, Victor
Format Journal Article
LanguageEnglish
Portuguese
Published Hospital San Pedro 10.02.2023
Emergency Department of Hospital San Pedro (Logroño, Spain)
Subjects
Health Care Sciences & Services
heart failure
nephroprotection
sglt2 inhibitors
type 2 diabetes mellitus
Heart failure
Nefroprotección
Diabetes mellitus tipo 2
Nephroprotection
Insuficiencia cardiaca
Inhibidores SGLT2
Type 2 diabetes mellitus
SGLT2 inhibitors
Online AccessGet full text

Cover

More Information
Summary:Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2 Inhibitors) initially entered the market to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM), however the discovery of the cardiovascular benefits in patients with HF, regardless of the presence or absence of T2DM positioned it as a new pillar in clinical management. In this state-of-the-art review resulting from a comprehensive literature search (Medline, Cochrane and EMBASE), we describe the impact of SGLT2 Inhibitors on mortality and rehospitalizations in patients with HF and we propose a therapeutic plan for patients with HF to maximizes the benefits.
ISSN:2695-5075
2695-5075
DOI:10.53986/ibjm.2023.0009